Inj tranexamic acid

The studies cited above used a variety of methods for extemporaneous compounding of TXA ranging from % to 10% solutions. Two methods have been suggested depending on the formulation used. ( 21275495 ) If the 100 mg/mL or 10% solution for injection is used, a 5% oral solution can be prepared by diluting 5 mL of tranexamic acid with 5 mL of sterile water. If the 500 mg tablets are available, one tablet can be placed into 20 mL of water, and stirred until the tablets are completely disintegrated to form a fine particular suspension. It is suggested that a maximum expiration date of five days should be employed if refrigerated, and the solution should be protected from light. 3  In the place of a 500 mg tablet, it seems that use of a 650 mg tablet dissolved in 20 mL could be safely used as well. This is supported by evidence in which a 500 mg tablet was dissolved in 10 mL of water with no reports of adverse events. ( 24808695 ) There is evidence to support that an even lower concentration may be effective, as a % solution was utilized by Kaewpradub and colleagues, although higher concentrations have safely been used.

Our extensive range of finished dosage formulations covers every aspect of human life. Our basket of formulations contain more than 850 products in several forms belonging to 45 therapeutic segments and 12 specialities including cardiovascular, gastrointestinal, analgesics, haematinics, anti-infectives and antibiotics, respiratory agents, antidiabetics, immunogicals and oncology. The manufacturing expertise is available for almost all dosage forms including sterile as well as non sterile products. Formulations has three manufacturing facility in the state of Gujarat, Jammu (India) and Ethiopia. All of which are approved by all prominent international regulatory bodies, including USFDA

Worldwide Postmarketing Reports: Thromboembolic events (., deep vein thrombosis, pulmonary embolism, cerebral thrombosis, acute renal cortical necrosis, and central retinal artery and vein obstruction) have been rarely reported in patients receiving tranexamic acid for indications other than hemorrhage prevention in patients with hemophilia. Convulsion, chromatopsia, and visual impairment have also been reported. However, due to the spontaneous nature of the reporting of medical events and the lack of controls, the actual incidence and causal relationship of drug and event cannot be determined.

Inj tranexamic acid

inj tranexamic acid


inj tranexamic acidinj tranexamic acidinj tranexamic acidinj tranexamic acidinj tranexamic acid